MARTIUS advises Dermapharm on the acquisition of C³ Group
Dermapharm Holding SE acquires C³ Cannabinoid Compound Company GmbH (C³ Group)
As the market leader for dronabinol in Germany and Austria, the C³ Group develops, produces and markets natural and synthetic cannabinoids In addition to C³ Cannabinoid Compound Company GmbH, the C³ Group includes the German subsidiaries Spectrum Therapeutics GmbH, based in Neumarkt, and THC Pharm GmbH The Health Concept, based in Frankfurt am Main, as well as Spectrum Therapeutics Austria GmbH, based in Vienna, Austria.
Dr. Philipp Kopp regularly advises Dermapharm on its acquisitions and investments in Germany, Austria and abroad.
Dermapharm was also advised on legal matters by Schindler Rechtsanwälte (Vienna) and on antitrust matters by Buntscheck Rechtsanwälte (Munich).
Point of contact
